Latest Kyowa Kirin News & Updates

See the latest news and media coverage for Kyowa Kirin. We track all announcements, press releases, and industry mentions in real time, all in one place.

Kyowa Kirin

Japan-based global specialty pharmaceutical company

kyowakirin.com

Headquarters: Chiyoda-ku, Japan
Company type: Public company
Number of employees: 5,000–10,000
Industry: Pharmaceuticals

Last updated September 8

Latest news about Kyowa Kirin

In short: Kyowa Kirin secured FDA priority review for infigratinib as first-half earnings surged.

Company announcements

September 8 Kyowa Kirin

Kyowa Kirin announces Phase 2 results for KHK4951 eye drops

The trial missed its primary endpoint due to a lack of dose-response superiority, while sixty-five to sixty-nine percent of participants preserved vision through week fifty-two.

August 31 Kyowa Kirin

Kyowa Kirin reaches a U.S. agreement to reduce patient drug costs

The deal includes Medicaid discounts, deferred tariffs, and sustained American manufacturing investments totaling $530 million.

August 3 Kyowa Kirin

Kyowa Kirin reports strong Q2 fiscal 2026 financial results

Revenue rose 14% and core operating profit surged 80%. The FDA selected its Sanford facility for a pilot program. R&D updates include positive ziftomenib data presented at EHA 2026.

May 12 Kyowa Kirin

Kyowa Kirin presents updated frontline ziftomenib data

Oral EHA 2026 presentation reports 99 patients, CRc 90–96%, MRD-negativity >80%, durable responses, and ongoing Phase 3 KOMET-017 enrollment.

Media coverage

September 1 Nikkei

Kyowa Kirin stock continues to fall; new drug candidate fails to meet primary endpoint in clinical trial

(12:30, Prime, Code 4151) Kyowa Kirin is continuing to fall. In the morning session, it hit a price of 2,183 yen, down 180 yen (7.61%) from the previous day. It remains lower in the afternoon session. On the 8th, in the Phase 2 international clinical trial for the new eye drop drug candidate 'KHK4951' targeting neovascular age-related macular degeneration...

August 30 Bloomberg

Trump US administration reaches agreement on drug prices with nine pharmaceutical companies - including Astellas and Kyowa Kirin

The Trump US administration has reached an agreement with nine biotechnology and pharmaceutical companies, including UCB, BridgeBio Pharma, and San Pharmaceutical Industries, regarding new drug pricing. Japanese companies Astellas Pharma and Kyowa Kirin have joined the agreement...

August 12 Nikkei

Kyowa Kirin, increased revenue and profit

[Increased revenue and profit] Sales of key products such as the rare bone disease treatment 'Crysvita' have been strong. Due to the discontinuation of development of the atopic dermatitis treatment 'Rocatinlimab', a one-time contract-related payment from the co-developing U.S. company was recorded in full. ... To the email address you registered ...

August 3 Zone Bourse

Kyowa Kirin: profit jumps 88% in first half

Kyowa Kirin's profit attributable to owners of the parent company jumped 88% to reach 30.6 billion yen during...

Never miss news about Kyowa Kirin

Track Kyowa Kirin and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Kyowa Kirin competitors & trending companies

Browse news for competitors to Kyowa Kirin and other trending companies.